vs
Side-by-side financial comparison of EXACT SCIENCES CORP (EXAS) and QuidelOrtho Corp (QDEL), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
EXACT SCIENCES CORP is the larger business by last-quarter revenue ($878.4M vs $699.9M, roughly 1.3× QuidelOrtho Corp). EXACT SCIENCES CORP runs the higher net margin — -9.8% vs -104.7%, a 94.9% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs -3.7%). EXACT SCIENCES CORP produced more free cash flow last quarter ($120.4M vs $-94.7M). Over the past eight quarters, EXACT SCIENCES CORP's revenue compounded faster (17.4% CAGR vs -2.9%).
Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
EXAS vs QDEL — Head-to-Head
Income Statement — Q4 2025 vs Q3 2026
| Metric | | |
|---|---|---|
| Revenue | $878.4M | $699.9M |
| Net Profit | $-86.0M | $-733.0M |
| Gross Margin | 70.1% | — |
| Operating Margin | -9.4% | -100.7% |
| Net Margin | -9.8% | -104.7% |
| Revenue YoY | 23.1% | -3.7% |
| Net Profit YoY | 90.1% | -3583.4% |
| EPS (diluted) | $-0.45 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $878.4M | — | ||
| Q3 25 | $850.7M | $699.9M | ||
| Q2 25 | $811.1M | $613.9M | ||
| Q1 25 | $706.8M | $692.8M | ||
| Q4 24 | $713.4M | $707.8M | ||
| Q3 24 | $708.7M | $727.1M | ||
| Q2 24 | $699.3M | $637.0M | ||
| Q1 24 | $637.5M | $711.0M |
| Q4 25 | $-86.0M | — | ||
| Q3 25 | $-19.6M | $-733.0M | ||
| Q2 25 | $-1.2M | $-255.4M | ||
| Q1 25 | $-101.2M | $-12.7M | ||
| Q4 24 | $-864.6M | $-178.4M | ||
| Q3 24 | $-38.2M | $-19.9M | ||
| Q2 24 | $-15.8M | $-147.7M | ||
| Q1 24 | $-110.2M | $-1.7B |
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
| Q4 25 | -9.4% | — | ||
| Q3 25 | -3.0% | -100.7% | ||
| Q2 25 | -0.3% | -29.4% | ||
| Q1 25 | -13.6% | 4.7% | ||
| Q4 24 | -122.8% | -14.2% | ||
| Q3 24 | -5.6% | 2.1% | ||
| Q2 24 | -3.8% | -18.4% | ||
| Q1 24 | -16.7% | -247.3% |
| Q4 25 | -9.8% | — | ||
| Q3 25 | -2.3% | -104.7% | ||
| Q2 25 | -0.1% | -41.6% | ||
| Q1 25 | -14.3% | -1.8% | ||
| Q4 24 | -121.2% | -25.2% | ||
| Q3 24 | -5.4% | -2.7% | ||
| Q2 24 | -2.3% | -23.2% | ||
| Q1 24 | -17.3% | -239.9% |
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $-0.10 | $-10.78 | ||
| Q2 25 | $-0.01 | $-3.77 | ||
| Q1 25 | $-0.54 | $-0.19 | ||
| Q4 24 | $-4.69 | $-2.54 | ||
| Q3 24 | $-0.21 | $-0.30 | ||
| Q2 24 | $-0.09 | $-2.20 | ||
| Q1 24 | $-0.60 | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $964.7M | $98.1M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $2.4B | $2.0B |
| Total Assets | $5.9B | $5.7B |
| Debt / EquityLower = less leverage | — | 1.23× |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | $98.1M | ||
| Q2 25 | $858.4M | $151.7M | ||
| Q1 25 | $786.2M | $127.1M | ||
| Q4 24 | $1.0B | $98.3M | ||
| Q3 24 | $1.0B | $143.7M | ||
| Q2 24 | $946.8M | $107.0M | ||
| Q1 24 | $652.1M | $78.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.5B | $2.0B | ||
| Q2 25 | $2.5B | $2.8B | ||
| Q1 25 | $2.4B | $3.0B | ||
| Q4 24 | $2.4B | $3.0B | ||
| Q3 24 | $3.2B | $3.2B | ||
| Q2 24 | $3.2B | $3.2B | ||
| Q1 24 | $3.1B | $3.3B |
| Q4 25 | $5.9B | — | ||
| Q3 25 | $5.9B | $5.7B | ||
| Q2 25 | $5.8B | $6.4B | ||
| Q1 25 | $5.7B | $6.5B | ||
| Q4 24 | $5.9B | $6.4B | ||
| Q3 24 | $6.7B | $6.8B | ||
| Q2 24 | $6.7B | $6.7B | ||
| Q1 24 | $6.4B | $6.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $151.7M | $-45.5M |
| Free Cash FlowOCF − Capex | $120.4M | $-94.7M |
| FCF MarginFCF / Revenue | 13.7% | -13.5% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 3.6% | 7.0% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $356.8M | $-153.1M |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $151.7M | — | ||
| Q3 25 | $219.9M | $-45.5M | ||
| Q2 25 | $89.0M | $-46.8M | ||
| Q1 25 | $30.8M | $65.6M | ||
| Q4 24 | $47.1M | $63.7M | ||
| Q3 24 | $138.7M | $117.9M | ||
| Q2 24 | $107.1M | $-97.9M | ||
| Q1 24 | $-82.3M | $-700.0K |
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | $-94.7M | ||
| Q2 25 | $46.7M | $-84.3M | ||
| Q1 25 | $-365.0K | $9.4M | ||
| Q4 24 | $10.7M | $16.5M | ||
| Q3 24 | $112.6M | $71.4M | ||
| Q2 24 | $71.2M | $-133.2M | ||
| Q1 24 | $-120.0M | $-66.8M |
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | -13.5% | ||
| Q2 25 | 5.8% | -13.7% | ||
| Q1 25 | -0.1% | 1.4% | ||
| Q4 24 | 1.5% | 2.3% | ||
| Q3 24 | 15.9% | 9.8% | ||
| Q2 24 | 10.2% | -20.9% | ||
| Q1 24 | -18.8% | -9.4% |
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | 7.0% | ||
| Q2 25 | 5.2% | 6.1% | ||
| Q1 25 | 4.4% | 8.1% | ||
| Q4 24 | 5.1% | 6.7% | ||
| Q3 24 | 3.7% | 6.4% | ||
| Q2 24 | 5.1% | 5.5% | ||
| Q1 24 | 5.9% | 9.3% |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
